The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
Open accessAbstract
Thiazolidinedione (TZD) insulin sensitizers have the potential to effectively treat a number of human diseases, however the currently available agents have dose-limiting side effects that are mediated via activation of the transcription factor PPARγ. We have recently shown PPARγ-independent actions of TZD insulin sensitizers, but the molecular target of these molecules remained to be identified. Here we use a photo-catalyzable drug analog probe and mass spectrometry-based proteomics to identify a previously uncharacterized mitochondrial complex that specifically recognizes TZDs. These studies identify two well-conserved proteins previously known as brain protein 44 (BRP44) and BRP44 Like (BRP44L), which recently have been renamed Mpc2 and Mpc1 to signify their function as a mitochondrial pyruvate carrier complex. Knockdown of Mpc1 or Mpc2 in Drosophila melanogaster or pre-incubation with UK5099, an inhibitor of pyruvate transport, blocks the crosslinking of mitochondrial membranes by the TZD probe. Knockdown of these proteins in Drosophila also led to increased hemolymph glucose and blocked drug action. In isolated brown adipose tissue (BAT) cells, MSDC-0602, a PPARγ-sparing TZD, altered the incorporation of (13)C-labeled carbon from glucose into acetyl CoA. These results identify Mpc1 and Mpc2 as components of the mitochondrial target of TZDs (mTOT) and suggest that understanding the modulation of this complex, which appears to regulate pyruvate entry into the mitochondria, may provide a viable target for insulin sensitizing pharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selective crosslinking with photo affinity probe. (A) Mitochondrial membranes (20 µg) from rat liver were incubated with the iodinated (125I) photo-probe (MSDC-1101) in the absence of any competing compound (lane 1); in the presence of 25 µM MSDC-0160 (lane 2); in the presence of 25 µM MSDC-0602 (lane 3); or in the presence of 25 µM MSDC-1473 (lane 4). Following exposure to UV light, samples were separated on one dimensional SDS-PAGE and the dried gel was exposed to X-ray film. (B) Active TZDs, but not MSDC-1473, produce a dose-dependent increase in UCP1 as detected on Western blots from mouse BAT progenitor cells. The abscissa shows drug concentration (µM). The inset on the top of this figure shows a representative Western blot of the increase in UCP1 protein in cells treated with an active TZD (pioglitazone). The data below the blot show the dose dependent increases observed in a representative experiment from a scan of the Western blots (arbitrary units, Mean and SE; N = 3). (C) Liver mitochondrial fractions from wild type or mitoNEET null mice [11] were crosslinked as in A without (−) or with (+) 25 µM MSDC-0160. The top figure is the resulting autoradiogram and the bottom is the Western blot for mitoNEET. (D) Mouse liver mitochondria were fractionated to generate fractions for outer membrane (OM), inter membrane space (IMS), inner membrane (IMM), and matrix. Total protein (10 µg) from each fraction was crosslinked as in A. The autoradiogram is shown at the top and a stain for total protein for the same 4 mitochondrial subfractions is shown below.](/paper-figures/c52128d21b004749b5d3eea8077be2ae/identification-of-a-mitochondrial-target-of-thiazolidinedione-insulin-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, the MPC has emerged as an unanticipated target of thiazolidinediones (Colca et al., 2013; Divakaruni et al., 2013), a class of insulin sensitizing drugs, and as a regulator of insulin secretion (Patterson et al., 2014; Vigueira et al., 2014);”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Colca et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Interplay between lipids and branched-chain amino acids in development of insulin resistance
Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.024 · Cited by 1,080
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., et al. (2010) · Nature · doi:10.1038/nature09291 · Cited by 897
A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and Humans
Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y.-C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., et al. (2012) · Science · doi:10.1126/science.1218099 · Cited by 843
Identification and Functional Expression of the Mitochondrial Pyruvate Carrier
Herzig, S., Raemy, E., Montessuit, S., Veuthey, J.-L., Zamboni, N., Westermann, B., Kunji, E. R. S., & Martinou, J.-C. (2012) · Science · doi:10.1126/science.1218530 · Cited by 747
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila
Musselman, L. P., Fink, J. L., Narzinski, K., Ramachandran, P. V., Hathiramani, S. S., Cagan, R. L., & Baranski, T. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007948 · Cited by 564
Kusminski, C. M., Holland, W. L., Sun, K., Park, J., Spurgin, S. B., Lin, Y., Askew, G. R., Simcox, J., McClain, D. A., Li, C., et al. (2012) · Nature Medicine · doi:10.1038/nm.2899 · Cited by 474
Satapati, S., Sunny, N. E., Kucejova, B., Fu, X., He, T. T., Méndez-Lucas, A., Shelton, J. M., Perales, J. C., Browning, J. D., & Burgess, S. C. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m023382 · Cited by 407 · cited 1×
“have shown that over activation of the TCA cycle is part of the pathology associated with over nutrition and hepatic insulin resistance [27] and this may also contribute to non-alcoholic fatty liver disease [28].”
BackgroundColca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00424.2003 · Cited by 342
Self-citation
Cited by
Sorted by citations
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 520
Self-citationCurrent and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2016) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 420
Metadata
- Authors
- Colca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., Gracheva, E., Korshunova, Y., Trusgnich, M., Karr, R., Wiley, S. E., Divakaruni, A. S., Murphy, A. N., Vigueira, P. A., Finck, B. N., & Kletzien, R. F.
- Affiliations
- Metabolic Solutions Development Company (United States) (US)
- University of California San Diego (US)
- Washington University in St. Louis (US)
- Corresponding author
- Colca, Jerry R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e61551
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3655167
- OpenAlex
- W2165311378
- Cited by
- 171
- References
- 30
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 12 · 2022: 14 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 15 · 2017: 20 · 2016: 17 · 2015: 8 · 2014: 17 · 2013: 9
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Michigan Economic Development Corporation
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (AA21228, R42AA021228)
- National Institute of Diabetes and Digestive and Kidney Diseases (R41DK084596, DK081298, DK84596, R42DK081298)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- thiazolidinediones, insulin sensitizers, mitochondrial pyruvate carrier, MPC1, MPC2, pyruvate transport, acetyl-CoA biosynthesis, brown adipose tissue, hemolymph glucose, Drosophila melanogaster, drug target identification
- MeSH terms
- Insulin Secretion, Amino Acid Sequence, Animals, Adipose Tissue, Brown, Drosophila melanogaster, Humans, Hypoglycemic Agents, Insulin, Mitochondria, Molecular Sequence Data, Sequence Homology, Amino Acid, Membrane Transport Proteins, Monocarboxylic Acid Transporters, Mitochondrial Membrane Transport Proteins, Thiazolidinediones, Gene Knockdown Techniques, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review